Christopher Clinton Conway: Gratitude and Progress – Research Leads
Christopher Clinton Conway, Chief Executive Officer and Board Executive Committee at Tower Cancer Research Foundation, shared a post on LinkedIn:
“Gratitude and Progress: Research Leads
The mission of Tower Cancer Research Foundation is research first. That’s in our name. Yet, today in Los Angeles, Tower is renowned as a vital hub of cancer community care through Magnolia House, a welcoming space serving thousands of patients and their families who come to us to find the support they need. And in just the past year and a half, we strengthened and diversified our services through collaborations with both Cancer Support Community Los Angeles and Lipstick Angels.
We know human services make a difference, every day, to those who need them, so Tower responds with generous resources. At the same time, Tower continues to grow in ambition and impact, funding pioneering cancer research here in southern California and beyond. The quest for breakthroughs is constant, and that insistence on identifying and supporting best in class researchers is frankly what attracted me to Tower.
Joining Tower after five years leading the Dr. Susan Love Fund for Breast Cancer Research meant an extraordinary opportunity to accelerate growth at Tower and link the legacy of Dr. Susan Love. Now Tower is powered by the determined and generous donors and researchers affiliated with both organizations, and that matters.
The continuous quest to do more to cure cancer that defines the Tower organization, and this board inspired me to lead the campaign to secure $1.9 million in funding from new donors and to found the Tower Cancer Research Collective. I’m pleased to say that the work does not end here; the foundation has been laid for more progress ahead.
Working with Tower staff and board to award grants to cancer researchers at every career stage who are pushing towards cures has made my time here meaningful, and I have fully realized the potential and power of Tower. My thanks to all of you for your generous support; as I step away from my role later this month, I feel confident that Tower Cancer Research Foundation is significantly strengthened and growing.”
More Posts Featuring Christopher Clinton Conway.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023